PHTD 2012 Spring Meeting - units.sla.org

PHTD 2012 Spring Meeting, Baltimore MD
20
Tuesday, March 20 (Morning)
9:15 – 10:30 am The Rise of China: Implications for Pharma and Pharma Librarians
Josh Berlin, Elsevier Business Intelligence
Historically, Big Pharma has concentrated mostly on three key markets (the U.S., Europe and
Japan), with China and other emerging markets given a lower priority. But in recent years, that
mindset has changed as companies struggle with the patent cliff and related challenges and
try to tap into rapidly growing emerging markets, particularly China.
China has now become the third largest pharmaceutical market, and many experts predict
it will overtake the U.S. in the next ten to 15 years to grab the top spot. On the back of
massive government healthcare reforms, China has created the world’s largest single-payer
system – representing 1.3 billion people – and the government has made funding of research
and innovation a priority. Not surprisingly, Big Pharma has flocked to China, opening R&D
facilities, rapidly expanding their commercial teams and incorporating China into global
development plans. Many are also experimenting with new business and R&D models in
response to huge unmet medical needs and affordability challenges.
Given its strategic importance, it is imperative that pharma librarians have a working
understanding of China and the unique content needs of the market. In this presentation, we
will provide an overview of the China pharma market, including a closer look at China’s $124
billion healthcare reforms, and also suggest helpful tips for librarians on how to find reliable
sources about pharma-related issues in China.
Biography
Joshua Berlin is executive editor & director of business development for Elsevier Business
Intelligence, a global publisher that provides analysis and insight on the biopharma and
medical devices industries. At EBI, Mr. Berlin leads emerging markets, including PharmAsia
News, a daily online publication that provides regulatory and business intelligence to
life sciences executives doing business in China, India and other Asian markets; and the
PharmAsia Summit, an annual strategic conference. He is also responsible for generating
business and editorial opportunities for a suite of industry-leading publications, including “The
Pink Sheet” and “IN VIVO.” EBI is a division of Elsevier, the world’s leading provider of science
and health information.
Prior to joining EBI, Mr. Berlin served as a manager in the life sciences practice at Ernst &
Young LLP where he helped advise organizations on regulatory best practices. Before that, he
served as a managing editor at Thompson Publishing Group in Washington, D.C., where he
oversaw publications related to U.S. FDA compliance and enforcement. Mr. Berlin is a board
member of the BioJudiciary Project, a 501(c)(3) organization with an educational mission
to help judges better understand technical and legal issues related to biotechnology, and a
member of the Loudoun County, Virginia, Science & Technology Cabinet.
F F F